Not recruitingISRCTN38094599
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
Research studyAges 18+Multiple countries
Understand this study
Who could participate?
This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- Canada · Denmark and 4 more locations
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Institut de Recherches Internationales Servier (France)
- Sponsor type
- Research institute
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- Canada, Denmark, Estonia, ...
- Age range
- Over 18 Years
- Official registry ID
- ISRCTN38094599
- Official title
Show the full official title
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Canada · Denmark · Estonia
3 more locations
- Finland
- Hungary
- Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier (France), a research institute.
Who can participate?
This study is for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not recruiting.
